IPO Boutique

Reata Pharmaceuticals IPO Advisory

Share this IPO Profile:

Smart Search
Company begins with...
Company contains...

For IPO Boutique's "scale of 1 to 5" BUY rating on Reata Pharmaceuticals, and our comprehensive analysis, click "Buy Market Research".
Company
Symbol
Price Range
Issue Price
Open
Shares
Trade Date
Reata PharmaceuticalsRETA -
NASDAQ
$14.00-$16.00 $11.00 $11.065.5 million5/26/2016
Citigroup, Cowen & Co., Piper Jaffray
Co-Manager(s):
Health Care
Filing(s):

Filed 2016-01-04
Terms Added 2016-05-16



Reata Pharmaceuticals Quote & Chart - Click for current quote - RETA

About Reata Pharmaceuticals (adapted from Reata Pharmaceuticals prospectus):
They are a clinical stage biopharmaceutical company focused on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a variety of serious or life-threatening diseases.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.



IPO Boutique aggregates information on public companies and private companies, such as "RETA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.

Used our Comprehensive Single Promo Advisory and want more?
We also offer a monthly or annual subscription






© 2005 - 2024 IPO Boutique. All Rights Reserved